易普利姆玛治疗晚期黑色素瘤有效性和安全性的Meta分析

发布时间：2018-03-09 22:05

本文选题：易普利姆玛　切入点：晚期黑色素瘤　出处：《重庆医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:对易普利姆玛治疗黑色素瘤患者的有效性及安全性进行meta分析。方法:计算机检索Pub Med,the Cochrane Library,Embase,中国知网、万方和维普数据库。依据设定的纳入及排除标准选取论文,并且提取信息、评估研究质量后,运用Rev Man 5.3软件对符合要求的研究进行meta分析。结果:经筛选后有4篇论文满足要求,纳入的病例总数是2622例。Meta分析结果显示:与对照组相比,易普利姆玛组1年无进展生存率(RR=0.94,95%CI:0.91~0.98,P=0.001)、1年总生存率(RR=0.79,95%CI:0.72~0.87,P0.00001)较高,具有统计学差异。2年无进展生存率(RR=0.99,95%CI:0.97~1.01,P=0.45)及3年总生存率(RR=0.93,95%CI:0.84~1.03,P=0.17)均无统计学差异。易普利姆玛组患者皮疹(RR=2.43,95%CI:1.64~3.61,P0.00001)、瘙痒(RR=2.35,95%CI:1.67~3.29,P0.00001)、腹泻(RR=1.82,95%CI:1.47~2.25,P0.00001)、结肠炎(RR=11.21,95%CI:6.20~20.30,P0.00001)、丙氨酸氨基转移酶增高(RR=3.57,95%CI:1.92~6.62,P0.0001)、天门冬氨酸氨基转移酶增高(RR=3.81,95%CI:2.85~5.09,P0.00001)的发生率均较高。结论:易普利姆玛可提高患者1年无进展生存率、1年总生存率,但在2年无进展生存率及3年总生存率方面未显示出优势,且易普利姆玛增加了患者出现皮疹、瘙痒、腹泻、结肠炎和转氨酶升高的风险。
[Abstract]:Objective: to analyze the efficacy and safety of Eprimma in the treatment of melanoma by meta. Methods: the Pub Medsite, the Cochrane Library Embase, the Wan-Fang and Weip databases were searched by computer, and the papers were selected according to the established inclusion and exclusion criteria. After extracting the information and evaluating the quality of the research, meta analysis was carried out by using Rev Man 5.3 software. Results: after screening, 4 papers met the requirements. The total number of cases included was 2622. Meta-analysis showed that compared with the control group, the 1-year progression-free survival rate of the Eprimma group was higher than that of the control group, and the 1 year overall survival rate was higher than that of the control group. There was no statistical difference in the 2-year progression-free survival rate (RRN 0.99 ~ 95CI0.97 P0.45) and the 3-year overall survival rate (RRN 0.9395CI0.84N 1.03P0.17). There was no statistical difference in the 2-year progressive survival rate (RR2.4395CI1.643.61C), RRR2.3595CI1.673.29P0.00001N) and the overall 3-year survival rate (RRR1.0395CI0.841.0395CI0.80.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395C0.17), RR2.395CI1.643.61C (P 0.00001), RRR1.82CI1.82CI1.82CI1.25P0.00001a, RR11.21a, CI6.2020.30P0011a, the elevation of the alanine aminotransferase R53.951a in R53.959CI1.000. The incidence of RRX 3.81C 95% CI: 2.85% 5.09% P0.00001) was higher. Conclusion: the 1-year progression-free survival rate and 1-year overall survival rate can be improved by Iprimma. But there was no advantage in 2-year progression-free survival and 3-year overall survival, and Eprimma increased the risk of rash, pruritus, diarrhea, colitis and elevated transaminase.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R739.5

【参考文献】